Trying NMN and EGA® to improve exercise ability in healthy older adults
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
This study will test whether the proprietary EGA® supplement or conventional NMN helps improve exercise endurance in healthy people aged 60–80.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 60 Years to 80 Years |
| Sex | All |
| Sponsor | Concordia University Chicago Academic / other |
| Locations | 1 site (Beverly Hills, California) |
| Trial ID | NCT07144527 on ClinicalTrials.gov |
What this trial studies
This randomized, double-blind, placebo-controlled, two-arm crossover trial compares a proprietary NAD+-modulating formulation (EGA®) with conventional nicotinamide mononucleotide (NMN) supplementation in healthy older adults. Participants will self-administer twice-daily oral doses that provide 1000 mg NMN per day, with the EGA® arm including two additional endogenous metabolomic compounds. The primary outcome is time to fatigue on constant work rate cycle ergometry, with secondary outcomes including VO₂peak, lactate threshold, anaerobic work capacity, critical power, and circulating NAD+ metabolites. The trial is designed to measure short-term physiological effects and safety under controlled exercise testing and will inform whether the proprietary combination offers added benefit over standard NMN.
Who should consider this trial
Good fit: Healthy adults aged 60–80 who have medical clearance for moderate-to-vigorous exercise, normal recent cardiac testing, MoCA ≥26, and the ability to perform structured cycling are ideal candidates.
Not a fit: People with uncontrolled medical conditions, significant cardiac abnormalities on recent testing, cognitive impairment (MoCA <26), or who cannot perform moderate-to-vigorous cycling are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the interventions could increase submaximal exercise tolerance and improve biomarkers related to aging in older adults.
How similar studies have performed: Prior human studies of NMN and other NAD+ precursors have shown modest and sometimes mixed improvements in metabolic markers and physical function, while EGA®'s specific proprietary combination has limited published clinical data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 60 to 80 years, of any sex * Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study * Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no significant valvular heart disease, no ischemic changes, and no other clinically significant abnormalities, plus confirmation that no new cardiovascular symptoms (e.g., chest pain, dyspnea, syncope) or changes in health status have occurred since testing * Montreal Cognitive Assessment (MoCA) score of 26 or higher * Free from acute or uncontrolled chronic medical conditions that would pose a risk or interfere with study participation * Physically capable of engaging in structured exercise involving moderate to vigorous intensity stationary cycling * Successful completion of a graded exercise test (e.g., stationary bike) without significant adverse events or contraindications * Ability to attend at least four in-person laboratory visits in Beverly Hills, California * Non-smoker for at least 12 months * Able to provide informed consent and comply with study procedures * Willing to refrain from initiating new exercise, dietary supplement, or medication regimens during the study Exclusion Criteria: * Severe cardiovascular disease (e.g., recent myocardial infarction \<6 months, unstable angina, uncontrolled hypertension \>160/100 mmHg) * Severe respiratory conditions (e.g., advanced COPD or other conditions preventing exercise participation) * Significant neurological impairments that hinder comprehension of instructions or participation in exercise * Terminal illness or conditions limiting life expectancy or ability to complete the study * Severe cognitive impairment preventing informed consent, protocol adherence, or comprehension of interventions * Significant orthopedic limitations or injuries that prevent safe exercise participation * Use of NMN, NR, or other NAD+-altering supplements within the past 14 weeks * Anticipated or current alcohol consumption \>2 drinks per week, or unwillingness to abstain from alcohol during the study * Current substance abuse affecting study participation or adherence * Other acute or chronic health conditions judged by the investigators to pose risk or interfere with study objectives * Non-compliance with study requirements, withdrawal of informed consent, or unforeseen circumstances compromising completion * Any condition which, in the opinion of the investigator, would interfere with study participation or interpretation of results
Where this trial is running
Beverly Hills, California
- Medical Office of Dr. Robert Huizenga MD — Beverly Hills, California, United States (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.